10/1/2013 9:47:24 AM
Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data will be presented
on the investigational protease inhibitor simeprevir for the treatment of
genotype 1 chronic hepatitis C in adult patients with compensated liver disease
at the upcoming Annual Meeting of the American Association for the Study of
Liver Diseases (AASLD), which will take place November 1 to 5 in Washington,
Help employers find you! Check out all the jobs and post your resume.
comments powered by